Arcturus Therapeutics Holdings Inc. Securities Fraud Investigation
April 13, 2026
Shamis & Gentile, P.A. is investigating claims on behalf of investors of Arcturus Therapeutics Holdings Inc. ("Arcturus Therapeutics" or the "Company") (ARCT). Impacted investors are advised to contact the firm now.
The law firm is investigating whether Arcturus Therapeutics and certain of its officers and/or directors made materially misleading statements or omissions regarding the development and efficacy of its ARCT-032 cystic fibrosis program between January 2025 and October 2025.
Throughout this period, the Company seemingly emphasized positive progress, active enrollment and an optimistic timeline for interim Phase II data, with management statements in May and August 2025 seemingly projecting confidence in meaningful clinical results. However, Arcturus Therapeutics may have omitted cautionary language about emerging efficacy concerns, particularly regarding the primary endpoint of FEV1 lung function improvement.
On October 22, 2025, Arcturus Therapeutics issued interim Phase 2 results for ARCT-032 that disclosed no meaningful improvement in FEV1 after 28 days, the study’s primary efficacy endpoint.
On this news, Arcturus Therapeutics' stock price fell $11.62 per share, or approximately 50%, to close at $11.54 on October 22, 2025, erasing significant market capitalization.
If you purchased Arcturus Therapeutics (NASDAQ: ARCT) securities between January 2025 and October 22, 2025, you may be eligible to seek compensation for your losses. Contact Shamis & Gentile today to discuss your options.
Shamis & Gentile, P.A. stands out as an advocate for investors who are victims of securities fraud. The firm is committed to securing recoveries for investors who have incurred damages due to false and misleading statements or other corporate misconduct by public companies. Shamis & Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise and resources enable the firm to resolve disputes in a wide range of matters, including class actions, mass torts and mass arbitrations.
Attorney advertising. Prior results do not guarantee similar outcomes.